TrialJournal of hematology & oncology2017

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Chongsheng Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.